Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 1998

View Archived Issues

Company Profile: CytoMed

Gliatech: Q4 and FY 1997 highlights

Sepracor: year-end 1997 highlights

Additional phase I/II data reported for Panretin Gel in KS

Genetix licenses gene therapy technologies from Dana-Farber

NIH offers potential tuberculosis vaccine technology for licensing

Milestone reached in Corvas/Pfizer NIF collaboration

Takeda exercises option to develop therapeutic protein

NIH will license technology that may lead to new HCV vaccines

Saruplase found equivalent to streptokinase in COMPASS trial

Neuropeptide Y Y2 agonists prepared at Peptech/CRC

Vitamin D analogues with promising profile from Leo

Role defined for Lp(a) in heart disease

Boehringer Ingelheim reveals new antiinflammatory agents

Penclomedine metabolite shows comparable anticancer efficacy, reduced neurotoxicity

Vitamin C protects blood vessels in diabetic patients

Anticoagulants under development at Astra

Cell Pathways/U. of Arizona study compounds for precancerous lesions

CFC-222 compared to other fluoroquinolones in vitro and in vivo

Ongoing clinical trials of Topiglan confirm positive early results

Phase I/II trial results reported for OncoVax-P formulated with JenVax-100a

Elan/Sano merger approved by Sano stockholders

Once-daily formulation of paroxetine submitted for FDA review

Select Therapeutics licenses cancer-related technology

NIH researchers discover how light shuts off melatonin production

Idec, SKB announce development plans for clenoliximab

Ten-year gene therapy collaboration initiated by Transgene and Human Genome Sciences

FDA okays labeling change for Pulmozyme

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...